All treatments
UvoWell Microdosing Semaglutide illustrative packaging
1 / 4

Illustrative packaging and scenes. Actual medication and packaging depend on the clinician and pharmacy; educational imagery does not promise outcomes.

Weight Management

Microdosing Semaglutide

Specific low-dose formulation, eligibility and supply are not yet confirmed. Microdosing is not an FDA-approved indication.

Injection · Prescription evaluation required

This is a proposed low-dose semaglutide pathway, separate from standard weight treatment. Its dose, supply and clinical purpose have not been confirmed.

  • A separate low-dose care discussion
  • Not the standard treatment program

Pricing to be confirmed

At-home preparation panels

Priced separately from treatment subscriptions. Testing and treatment eligibility are determined by your clinician.

GLP-1 weight-loss preparation panel
$129

Enrollment pending confirmation. A notification request is not a medical assessment or purchase.

Clinician-selected careSuitability reviewed individually

Treatment details

Formulation & delivery

Specific low-dose formulation, eligibility and supply are not yet confirmed. Microdosing is not an FDA-approved indication.

Who may be eligible?

Adults with a relevant concern may be evaluated. A licensed OpenLoop clinician reviews medical history, current medications and any required testing. Browsing treatments does not establish eligibility.

A considered decision

Potential benefits

Potential outcomes depend on the product, indication and individual. Benefits are not guaranteed.

  • A separate low-dose care discussion
  • Not the standard treatment program

Important information

Risks & limitations

Nausea, vomiting, diarrhea, constipation and dehydration may occur. Serious risks include pancreatitis and gallbladder problems. GLP-1 medications may be inappropriate with certain thyroid cancer histories or MEN2 and during pregnancy. Clinicians review product-specific risks.

Microdosing is not an FDA-approved indication. Standard-dose trial results cannot be transferred to an unspecified lower-dose regimen.

This is not a complete list of risks. Review product-specific information and alternatives with your clinician. Compounded products are not FDA-approved.

The science, in context

How Microdosing Semaglutide works

This is a proposed low-dose semaglutide pathway, separate from standard weight treatment. Its dose, supply and clinical purpose have not been confirmed.

Semaglutide

Activates GLP-1 receptors involved in appetite and blood-glucose regulation.

Microdosing is not an FDA-approved indication. Standard-dose trial results cannot be transferred to an unspecified lower-dose regimen.

Your path to care

01

Choose your desired therapy

Explore treatments by concern. Choosing a treatment is not a medical eligibility decision.

02

Complete a clinical assessment

When enrollment is available, the verified treatment link takes you to OpenLoop’s intake. Share your history and current medications.

03

Receive a clinician’s care plan

A licensed clinician evaluates suitability and any required labs. A prescription is issued only when appropriate.

04

Continue care with follow-up

If prescribed, a pharmacy fulfills your treatment. Your care team determines monitoring and any adjustments.

Billing, supply & follow-up

An initial payment and renewal schedule have not been confirmed. No payment is collected on this preview page. We will not direct you to a checkout until its price, clinical pathway and formulation match the treatment shown.

Medication quantity, shipping costs, refill timing and follow-up services must be confirmed for the selected plan. Lab testing may be required. See our cancellation policy.

Microdosing Semaglutide FAQs

Other options to explore

Illustrative injection packaging for SemaglutideInjection

Weight Management

Semaglutide

Semaglutide treatment program. Current formulation, dose coverage and quantity require confirmation; dose is clinician-selected.

A standard GLP-1 pathway for weight management and appetite support.

$219 every four weeks

Proposed plan · enrollment pending confirmation

Care coaching proposed; exact inclusions and dose coverage require confirmation.

Explore treatment
Illustrative injection packaging for TirzepatideInjection

Weight Management

Tirzepatide

Tirzepatide treatment program. Current formulation, dose coverage and quantity require confirmation; dose is clinician-selected.

A standard dual GIP/GLP-1 pathway for weight management.

$309 every four weeks

Proposed plan · enrollment pending confirmation

Care coaching proposed; exact inclusions and dose coverage require confirmation.

Explore treatment
Illustrative injection packaging for Microdosing TirzepatideInjection

Weight Management

Microdosing Tirzepatide

OpenLoop support for this specific product and low-dose pathway must be confirmed. Not available for enrollment.

A potential low-dose pathway pending product and flow confirmation.

Pricing to be confirmed

Explore treatment

Prescription treatment requires approval by a licensed clinician. Results vary, and treatment is not appropriate for everyone. Compounded medications are not FDA-approved and have not been reviewed by the FDA for safety, effectiveness or quality. Lifestyle scenes and packaging are illustrative, not actual patients, clinicians or a guarantee of supplied packaging.

Microdosing Semaglutide

Price pending